Pharm Exec4d
FDA Grants Fast Track Designation to Adicet Bio’s CAR T-cell Therapy for Systemic Lupus Erythematosus
The FDA has granted Fast Track Designation to Adicet Bio’s ADI-001, an allogeneic gamma delta CAR T-cell therapy, for ...
Targeted Oncology3d
FDA Grants Key Oncology Approvals and Designations in January 2025
On January 7, 2025, the FDA granted priority review to the new drug application for sunvozertinib (DZD9008), an oral EGFR ...
Adicet Bio granted fast track designation for ADI-001 by FDA
Adicet Bio (ACET) announced the FDA has granted fast track designation to ADI-001 for the potential treatment of adult patients with refractory ...
Adicet Bio Gets Fast Track Designation For ADI-001 In Refractory Systemic Lupus Erythematosus
Adicet Bio, Inc. (ACET), a clinical stage biotechnology company, Wednesday said it received Fast Track Designation from the U.S. Food ...
Hosted on MSN2d
FDA fast tracks Bracco’s BR55 for Crohn’s disease bowel inflammation detection
Engineered to specifically act on the vascular endothelial growth factor receptor 2 (VEGFR2), BR55 (perfluorobutane/nitrogen ...
Pharmabiz32m
AbbVie receives US FDA approval for Emblaveo to treat adults with complicated intra-abdominal infections with limited or no treatment options
AbbVie receives US FDA approval for Emblaveo to treat adults with complicated intra-abdominal infections with limited or no treatment options: North Chicago, Illinois Monday, Febr ...
Medical Design and Outsourcing3d
NIH funds fast-tracked development of fetal hydrocephalus shunt
A team in Pittsburgh received a $2.3 million grant to fast-track the development and clinical transition of a minimally ...
Dyne Therapeutics, Inc. (DYN): Among the Best Rebound Stocks to Invest In Now
We recently compiled a list of the 10 Best Rebound Stocks To Invest In Now. In this article, we are going to take a look at ...
Recycling Today4dOpinion
Commentary: NextLoopp offers a path to using food-grade recycled polypropylene in food-contact packaging
NextLoopp Americas aims to mobilize U.S.-based organizations to participate in closing the loop on the most prolific fraction ...
Lipocine plans phase 3 study for postpartum depression drug
SALT LAKE CITY - Lipocine Inc. (NASDAQ: NASDAQ:LPCN), a biopharmaceutical company with a market capitalization of approximately $24 million, announced today that it will conduct a phase 3 safety and ...